¡¦¼£Îŷײè¤Ë¤Ä¤¤¤Æ¡¡
¡¡¼£ÎÅË¡¤È¤·¤Æ¤Ï¡¢ËÜË®¤Ç¤Ï¼ê½Ñ¡¢Êü¼ÍÀþ¤ª¤è¤Ó²½³ØÎÅË¡¤Ê¤É¤¬¤¢¤ë¤¬¡¢¼çÂΤȤʤë¤â¤Î¤Ï¼ê½ÑÎÅË¡¤ÈÊü¼ÍÀþÎÅË¡¤Ç¤¢¤ë¡£¼ê½ÑÎÅË¡¤Ï0, I¤ª¤è¤ÓII´ü´â¤À¤±¤Ë¹Ô¤¤¡¢­·,­¸´ü¤Î´â¤Ë¤Ï¸¶Â§¤È¤·¤Æ¼ê½ÑÎÅË¡¤Ï¹Ô¤ï¤Ê¤¤¤È¤µ¤ì¤Æ¤¤¤ë¡£Êü¼ÍÀþÎÅË¡¤Ï¡¢¼ç¤È¤·¤Æ¼ê½ÑÉÔǽÎ㤬¤½¤ÎÂоݤȤʤ롣¤¿¤À¤·¡¢²¤ÊƤǤÏ1999ǯ¤ËÊƹñ¹ñΩ¤¬¤ó¸¦µæ½ê¤Ï¡Ö¿Ê¹Ô´ü»ÒµÜðô¤¬¤ó¤ËÂФ·¤ÆÊü¼ÍÀþ¼£ÎŤȥ·¥¹¥×¥é¥Á¥ó¤ò¼çÂΤȤ¹¤ë²½³ØÎÅË¡¤òƱ»þÊ»ÍѤ¹¤ë¤³¤È¤ÏÀ¸Â¸Î¨¤òÍ­°Õ¤Ë²þÁ±¤·¡¢Í­¸ú¤Ê¼£ÎÅË¡¤Ç¤¢¤ë¡×¤È¤Î¥¢¥Ê¥¦¥ó¥¹¤¬½Ð¤µ¤ì¤Æ¤ª¤ê¡¢¤³¤Î¥¢¥Ê¥¦¥ó¥¹¤¬¤â¤¿¤é¤·¤¿±Æ¶Á¤ÏÂ礭¤¯¡¢²¤ÊƤǤϸ½ºß¤Ï¿Ê¹Ô´ü»ÒµÜðô¤¬¤ó¤ËÂФ·¤Æ¤Ï²½³ØÊü¼ÍÀþ¼£ÎŤ¬É¸½à¼£ÎŤȤµ¤ì¤Æ¤¤¤ë¡£¼ÂºÝ¤Ë¤Ï¡¢¤É¤Á¤é¤Î¼£ÎÅË¡(¼ê½ÑÎÅË¡¡¢¤â¤·¤¯¤ÏÊü¼ÍÀþ¼£ÎÅ)¤òÁªÂò¤·¤Æ¤â¤Û¤ÜƱÅù¤Î¼£ÎÅÀ®ÀÓ¤¬¾å¤²¤é¤ì¤Æ¤¤¤ë¡£°ìÈ̤ˡ¢»ÒµÜðôÉô¤ËȯÀ¸¤¹¤ë٨ʿ¾åÈé´â¤Ï¡¢Æ¬ðôÉô´â¤ä¿©Æ»´â¤Ê¤É¤Î٨ʿ¾åÈé´â¤è¤ê¤âÎɹ¥¤ÊÊü¼ÍÀþ¾È¼Í¸ú²Ì¤ò¼¨¤¹¾ì¹ç¤¬Â¿¤¤¡£¤³¤Î¤¿¤áÂ礭¤Ê¼ðáç¤Ç¤¢¤Ã¤Æ¤âÊü¼ÍÀþ¼£ÎŤǼ£Ìþ¤¬¤«¤Ê¤ê´üÂԤǤ­¤ë¤È¹Í¤¨¤é¤ì¤ë¡£
¡¡ËܾÉÎã¤Ï¡¢¥¹¥Æ¡¼¥¸­¶b´ü¤Î»ÒµÜðô´â¡¢ÁÈ¿¥¿Ç¤Ë¤Æ¹âʬ²½·¿¤Î³Ñ²½À­Ù¨Ê¿¾åÈé´â¤È¿ÇÃǤµ¤ì¤Æ¤¤¤ë¡£FIGO¤ª¤è¤ÓNCCN Clinical Practice Guidelines in Oncorogy¤Ë¤è¤ì¤Ð¡¢¤È¤â¤ËËܾÉÎã¤Ç¤Ï²½³ØÊü¼ÍÀþÎÅË¡¡Ü¹ÐÆâ¾È¼Í¤¬¿ä¾©¤µ¤ì¤Æ¤¤¤ë¡£¸¶È¯¼ðáç¤Î¥µ¥¤¥º¤Ï¡¢½ÅÍפÊͽ¸å°ø»Ò¤Ç¤¢¤ê¡¢»êŬ¼£ÎÅË¡¤ÎÁªÂò¤Ë¤¢¤¿¤Ã¤Æ¤Ï¿µ½Å¤Ëɾ²Á¤¹¤Ù¤­¤Ç¤¢¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£ËܾÉÎã¤Ç¤Ï¡¢»ÒµÜðôÉô¤¬40mm¤òĶ¤¨¤Æ¼ðÂ礷¤Æ¤¤¤ë٨ʿ¾åÈé´â¤Ç¤¢¤ê¡¢Êü¼ÍÀþÎÅË¡¤ò°ì¼¡¼£ÎŤȤ¹¤Ù¤­¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤Þ¤¿PDQ¤Ë¤è¤ì¤Ð¡¢Âè­·Áê¥é¥ó¥À¥à²½»î¸³5·ï¤Ë¤è¤Ã¤Æ¡¢¥·¥¹¥×¥é¥Á¥ó¥Ù¡¼¥¹¤Î²½³ØÎÅË¡¤ÈÊü¼ÍÀþÎÅË¡¤È¤ÎƱ»þÊ»ÍÑÎÅË¡¤¬Á´À¸Â¸¤ËÍ­Íø¤Ç¤¢¤ë¤³¤È¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¤È¼¨¤µ¤ì¤Æ¤¤¤ë¡£¸Î¤Ë¡¢Êü¼ÍÀþ¼£ÎŤ¬Âè°ìÁªÂò¤È¤Ê¤ê¤¦¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤Þ¤¿¡¢1)ËܾÉÎã¤Ç¤Ï¥ê¥ó¥ÑÀឰܤ¬¤¢¤ê¡¢½Ñ¸å¾È¼Í¤ò¹Ô¤¦É¬Íפ¬¤¢¤ë¤¿¤á¡¢¼ê½Ñ¤¹¤ë¤Ë¤·¤Æ¤âÊü¼ÍÀþ¼£ÎŤ¬É¬Íפˤʤ뤳¤È¡¢2)¼£ÎÅÀ®ÀӤϼê½ÑÎÅË¡¤ÈÊü¼ÍÀþÎÅË¡¤ÇÊѤï¤é¤Ê¤¤¤Ë¤âÊѤï¤é¤º¡¢¼ê½Ñ¤Ë¤è¤ë¿¯½±À­¤Ë¤è¤Ã¤Æ¿À·ÐÁѤλ½ý¤Ë¤è¤ëľIJç¯æù¾ã³²¤ä¥ê¥ó¥ÑÉâ¼ð¡¢ç¯æùç´áñ¡¢Ç¢´Éç´áñ¡¢Ä¾Ä²ç´áñ¤È¤¤¤Ã¤¿½Ñ¸å¹çÊ»¾É¤¬ÌäÂê¤È¤Ê¤ë²ÄǽÀ­¤¬¤¢¤ë¡¢3)¼ðáçºÇÂç·Â¤¬40mm¤ÈÂ礭¤¤­¶´ü¤Î´â¤Ç¤¢¤ë¤¿¤á¡¢CCRT¤ÎŬ±þ¤¬Ë¾¤Þ¤·¤¤¡¢¤Ê¤É¤ÎÍýͳ¤«¤é¡¢Êü¼ÍÀþÎÅË¡(²½³ØÎÅË¡´Þ¤à)¤ÎÁªÂò¤¬»Ù»ý¤µ¤ì¤ë¤È¹Í¤¨¤é¤ì¤ë¡£
¡¡¼£ÎÅÆâÍƤȤ·¤Æ¤Ï¡¢½µ1²ó¤Î²½³ØÎÅË¡¤È¤·¤Æ¥·¥¹¥×¥é¥Á¥ó(40mg/m2/week)¤òÀÅÃí¤·¡¢¤«¤Ä30Gy¤Î³°Éô¾È¼Í¤Î¸å¡¢20Gy¤Î¹ÐÆâ¾È¼Í¡¢¤¹¤Ê¤ï¤ÁÁíÀþÎÌ50Gy¤Î¾È¼Í¤ò¹Ô¤¦Í½Äê¤Ç¤¢¤ë¡£Àþ¼ï¤ÏXÀþ¤Ç¤¢¤ê¡¢ÀþÎ̤Ï10MV¤Ç¤¢¤ë¡£¾È¼ÍÊýË¡¤ÏÁ°¸åÂиþ2Ìç¤Ç¼Â»Ü¤·¡¢¾È¼ÍÈϰϤϻҵܡ¢ÉÕ°´ï¡¢ç´¤ÎƬ¦1/3¡¢»ÒµÜ˵·ë¹ç¿¥(´ðð×ÂÓ¡¢ç¯æù»ÒµÜð×ÂӤʤÉ)¤ª¤è¤Ó¹üÈ×Æâ¥ê¥ó¥ÑÀá¤Ç¤¢¤ê¡¢¾È¼ÍÌî¤Ï¡¢¾å±ï¤ÏÂè5¹øÄǾå±ï¡¢²¼±ï¤ÏÊĺ¿¹¦²¼±ï¡¢º¸±¦¤Î³°Â¦¤Ï¾®¹üÈ׹Ф«¤é1¡Á2cm³°Â¦¤È¤¹¤ë¡£¼£ÎÅ¥¹¥±¥¸¥å¡¼¥ë¤Ï½µ5²ó¾È¼Í¤Îñ½ãʬ³ä¾È¼Í¤Ç¡¢½µ´ÖÉÂÁãÀþÎ̤ò10.0GyÁ°¸å¤È¤¹¤ë¡£¹ÐÆâ¾È¼Í¤Ï¹âÀþÎÌΨ(HDR)¼£ÎŤǤ¢¤ë¡£¡¡

¡¦¼£ÎÅÀ®ÀӤˤĤ¤¤Æ
¡¡­¶´ü¤Î»ÒµÜðô´â¤ÎÊü¼ÍÀþ¼£ÎÅÀ®ÀÓ¤Ï5À¸Î¨¤Ç¤ß¤ë¤È60%¡Á80%¤Ç¤¢¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢Calfornia Endocurietherapy Cancer Center¤ÎÄ´¤Ù¤Ë¤è¤ì¤Ð¡¢27ÎãÃæ25Îã(93%)¤Î¶É½êÀ©¸æ¤ä22Îã(81%)¤Î¹üÈ×ÆâÀ©¸æ¤¬ÆÀ¤é¤ì¡¢±ó³Öž°Ü¤òµ¯¤³¤·¤¿¤Î¤Ï9Îã(33%)¤È¤¤¤¦À®ÀÓ¤òÆÀ¤¿¡£
¡¡¤Þ¤¿¡¢ËܾÉÎã¤Î¼£ÎÅÊý¿Ë¤Ç¤¢¤ëCCRT(concurrent chemoradiation , Ʊ»þÊ»ÍѲ½³ØÊü¼ÍÀþÎÅË¡)¤Ë¤Ä¤¤¤Æ¤Ï¡¢11¤ÎÎ×¾²»î¸³¤òÍѤ¤¤¿¥á¥¿¥¢¥Ê¥ê¥·¥¹(Green ,IA et al Iancet 358:781-86 2001)¤Ë¤è¤ì¤Ð¡¢CCRT¤Ë¤è¤Ã¤ÆÁ´ÂΤÇÀ¸Â¸Î¨¤¬12%¡¢ÈóºÆȯÀ¸Â¸¤¬16%¸þ¾å¤·¤Æ¤ª¤ê¡¢CCRT¤Ë¤è¤êÀ®ÀÓ¤¬¸þ¾å¤·¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤ë(¤¿¤À¤·¡¢µÞÀ­Í­³²»ö¾Ý¤âÁý²Ã¤·¤Æ¤¤¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë)¡£¤Þ¤¿¡¢1999ǯ¡Á2004ǯ¤Ë¤«¤±¤Æ6¤Ä¤ÎÂ絬Ìϥȥ饤¥¢¥ë¤¬¹Ô¤ï¤ì¤Æ¤¤¤ë(GOG123¡¢SWOG8797¡¢RTOG9001¡¢GOG85¡¢GOG120¡¢NCIC)¡£¤³¤ì¤é¤¹¤Ù¤Æ¤Î»î¸³¤Ë¤ÏCDDP¤¬ÍѤ¤¤é¤ì¤Æ¤ª¤ê¡¢1)Áá´üÎã¤òÂоݤˡ¢¼ê½Ñ¤ÈÁȤ߹ç¤ï¤»¤¿CCRT¤ÎÍ­ÍÑÀ­¤Ë¤Ä¤¤¤Æ¤ÎÄ´ºº 2)¿Ê¹ÔÎã¤òÂоݤËRT¤ÈCCRT¤Îº¹¡¢Å¬ÀÚ¤ÊÌôºÞ¤Î·èÄê¤Ë¤Ä¤¤¤Æ¤ÎÄ´ºº ¤¬¤Ê¤µ¤ì¤Æ¤¤¤ë¡£1)¤Ë´Ø¤·¤Æ¤ÏRTñÆÈ¢ª¥¢¥¸¥å¥Ð¥ó¥È»ÒµÜŦ½Ð½Ñ¤Ç¤Ï3ǯÀ¸Â¸Î¨¤Ç74%¡¢CCRT¢ª¥¢¥¸¥å¥Ð¥ó¥È»ÒµÜŦ½Ð½Ñ¤Ç¤Ï83%¤ÈÍ­°Õ¤Êº¹¤¬¸«¤é¤ì¤¿¡£2)¤Ë´Ø¤·¤Æ¤Ï¡¢weekly CDDP¤ÈCDDP/5FU/HU¤Ç¤Ï¡¢À¸Â¸Î¨¤ËÍ­°Õ¤Êº¹¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¡£¤Þ¤¿¡¢µÞÀ­Í­³²»ö¾Ý¤Ë´Ø¤·¤Æ¤Ïwekly CDDP < CDDP/5FU¤Ç¤¢¤ë¤¿¤á¡¢Æ±»þÊ»ÍѲ½³ØÎÅË¡¤È¤·¤Æ¤Ïweekly cisplatin¤¬¤è¤¤¤È¹Í¤¨¤é¤ì¤ë¡£¤µ¤é¤Ë¡¢ËܾÉÎã¤Î¤è¤¦¤Ë¿Ê¹ÔÎã¤Þ¤¿¤Ï¥ê¥ó¥ÑÀឰܤò¤­¤¿¤·¤¿¾ÉÎã(­µb>5cm¡Á­¸a¡¡¤Þ¤¿¤ÏLN positive)¤òÂоݤˤ·¤¿»î¸³¤È¤·¤Æ¤Ï¡¢NCIC(¥«¥Ê¥À)¤Ë¤ª¤¤¤ÆCCRT(weekly CDDP) vs RT(¹üÈ׾ȼͤΤß)¤Ç¤ÎÂоȤÎÎ×¾²»î¸³¤¬¹Ô¤ï¤ì¤¿¡£·ë²Ì¤È¤·¤Æ¤Ï¡¢Á°¼Ô¤¬62%¤Ç¸å¼Ô¤¬58%¤È¤¤¤¦·ë²Ì¤¬ÆÀ¤é¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢CCRT¤Ë´Ø¤¹¤ëÂ絬Ìϥȥ饤¥¢¥ë¤ÎÀ¸Â¸Î¨¤ÎÈæ³Ó(¾åµ­GOG85¤Ê¤É)¤Ç¤â¡¢CCRT¤ÇÀ¸Â¸Î¨¤Î¸þ¾å¤¬¸«¤é¤ì¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢¼£ÎŤËȼ¤¦ÉûºîÍѤȤ·¤Æ¤Ï¡¢°Ê²¼¤Î¤è¤¦¤Ê¤â¤Î¤¬¤¢¤ë¡£µÞÀ­´ü¤Ëµ¯¤³¤ë°­¿´¡ÊÊü¼ÍÀþ½É¿ì¡Ë¡¢²¼Î¡¡¢ç¯æù±ê¡¢ÈéÉæ±ê¡ÊÆä˲¼Êý¤Ë±äŤ·¤¿¾È¼ÍÌî¤ò¤È¤Ã¤¿¾ì¹ç¤Î²ñ±¢Éô¡Ë¡¢Çò·ìµå¸º¾¯¤Ê¤É¤¬µ¯¤³¤ë¡£ÈÕȯÀ­¡Êgrade3°Ê¾å¤ÎÉÑÅ١ˤιçÊ»¾É¤È¤·¤Æ¤Ï¡¢Ä¾Ä²±ê¡Ê½Ð·ì¡Ë¡Ê5¡Á10¡ó¡Ë¡¢ç¯æù±ê¡Ê½Ð·ì¡Ë¡Ê5¡ó°Ê²¼¡Ë¡¢¾®Ä²¾ã³²¡ÊIJÊĺɡˡÊ5¡ó°Ê²¼¡Ë¡¢Èé²¼ÁÈ¿¥Àþ°Ý²½¡¦Éâ¼ð¡Ê²¼Ê¢Éô¡Ë¡¢çµÇ´Ëì¤ÎÌþÃ塦ÄÙáç¡¢ç¯æùçµáñ¡¢Ä¾Ä²çµáñ¡¢¹üÀÞ¡¢²¼»èÉâ¼ð¤Ê¤É¤¬µ¯¤³¤ë¡£Âнè¤È¤·¤Æ¤Ï¡¢¼£Îų«»Ï2½µ¡Á3½µ¤Ëµ¯¤³¤ë¾È¼Í¤äÆâ¤ÎIJ´É¤Ë¤ª¤±¤ë¥À¥á¡¼¥¸¤Î¤¿¤á¡¢¿åʬ¤ÎµÛ¼ýÄã²¼¤ä²¼Î¡¤¬µ¯¤³¤Ã¤Æ¤¤¤ë¤È¤­¤Ë¤Ï¡¢À°Ä²ºÞ¤ä²¼Î¡»ß¤á¤òÍѤ¤¤ë¡£ÈÕ´üÍ­³²»ö¾Ý(¾®Ä²¡¦Ä¾Ä²¾ã³²¤äç¯æù¾ã³²)¤Ï¡¢°ìÅÙȯÀ¸¤¹¤ë¤Èº¬¼£¤¬º¤Æñ¤È¤µ¤ì¤Æ¤¤¤ë¡£
¡¡Í­³²»ö¾Ý¤Ë´Ø¤·¤Æ¤Ï¡¢JROSGÉؿͲʥ°¥ë¡¼¥×¤Ë¤ª¤±¤ë¸¦µæ¤ÇÄ´ºº¤µ¤ì¤Æ¤¤¤ë¡£¾È¼ÍñÆȤÈCCRT¤ÇÈæ³Ó¤·¤¿¾ì¹ç¡¢Çò·ìµå¸º¾¯(RTñÆȤǤÏ2.8% vs CCRT¤Ç62.5%)¡¢·ì¾®Èĸº¾¯(0.6% vs 13.9%)¡¢²¼Î¡¡¢ÉÑÇ¢¡¢ç¯æù±ê¤Ç¤Ï¤Û¤ÜƱΨ¡¢Ä¾Ä²±ê(2.8% vs 4.2%)¡¢¾®Ä²ÂçIJ¥¤¥ì¥¦¥¹(1.7% vs 6.9%)¤È¤Î·ë²Ì¤¬ÆÀ¤é¤ì¤¿¡£²½³ØÎÅË¡¤òÊ»ÍѤ¹¤ë¾ì¹ç¡¢ÌÀ¤é¤«¤Ë·ìµå¸º¾¯¤¬µ¯¤³¤ëΨ¤¬Áý²Ã¤·¤Æ¤ª¤ê¡¢¤½¤ÎÅÀ¤ËÃí°Õ¤¹¤ëɬÍפ¬¤¢¤ë¡£¸½ºß¡¢·ìµå¸º¾¯¤ËÂФ·¤ÆÇò·ìµå¸º¾¯ÍÞÀ©ºÞ¤òÅêÍ¿¤¹¤ë¤³¤È¤ÇÍ­³²»ö¾Ý¤Î·Ú¸º¤Î̵ͭ¤ò¤ß¤ëÎ×¾²»î¸³¤¬¹Ô¤ï¤ì¤Æ¤¤¤ë¤Ê¤É¡¢Í­³²»ö¾Ý¤ËÂФ¹¤ëÂкö¤¬¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£